Abstracts Archive - Page 945 of 2607 - ACR Meeting Abstracts

Abstract Number: 1629 • ACR Convergence 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Kimmi Cox³, Simon Helfgott⁴, Alexander Hu⁵, Kent Kwas Huston⁶, Jordan Leonard⁷, Scott Milligan³, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³Trio Health, Louisville, CO, ⁴BWH- HMS, Boston, MA, ⁵Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁶Kansas City Physician Partners, Kansas City, MO, ⁷Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Infusion reactions and other adverse events associated with pegloticase may lead to discontinuation of treatment in patient populations that have already failed or are…
Abstract Number: 1630 • ACR Convergence 2020
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Lars Iversen¹, Christopher EM Griffiths², Andrea Peserico³, Ignasi Pau-Charles⁴, Andrew Blauvelt⁵, Diamant Thaçi⁶ and Kristian Reich⁷, ¹Aarhus University Hospital, Aarhus, Denmark, ²The University of Manchester, Manchester, United Kingdom, ³DIMED University of Padua, Padua, Italy, ⁴Almirall R&D, Barcelona, Spain, ⁵Oregon Medical Research Center, Portland, OR, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…
Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 1632 • ACR Convergence 2020
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Joerg Henes¹, Norbert Blank², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Markus Hufnagel⁶, Tilmann Kallinich⁷, Birgit Kortus-Goetze⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, ⁷Charite, Berlin, Germany, ⁸Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully treated with the anti-IL-1ß inhibitor canakinumab.…
Abstract Number: 1633 • ACR Convergence 2020
A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Laura Schanberg¹, Peter Nigrovic², Ashley Cooper³, Winn Chatham⁴, Shoghik Akoghlanian⁵, Namrata Singh⁶, C. Egla Rabinovich⁷, Akaluck Thatayatikom⁸, Alysha Taxter⁹, Jonathan Hausmann¹⁰, Milan Zdravkovic¹¹, Sven Ohlman¹¹, Henrik Andersson¹¹, Susanna Cederholm¹¹, Gunilla Huledal¹¹, Rayfel Schneider¹² and Fabrizio De Benedetti¹³, ¹Duke University Medical Center, Durham, NC, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ³Children's Mercy Kansas City, Kansas City, MO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Nationwide Children’s Hospital, Columbus, ⁶University of Washington, Bellevue, WA, ⁷Duke University Hospital, Durham, NC, ⁸Department of Pediatrics, University of Florida, Gainesville, FL, ⁹Wake Forest Baptist Medical Center, Winston-Salem, ¹⁰Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹¹Sobi, Stockholm, Sweden, ¹²University of Toronto, The Hospital for Sick Children, Toronto, Canada, ¹³Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Still’s disease, including both systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD), is a rare systemic auto-inflammatory disorder associated with an activated…
Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 1635 • ACR Convergence 2020
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
Amy Kenneally¹, Frédérique Bariguian², Richard Petruschke¹, Arlene Tave³, Jess Edison⁴, Nicholas M. Sicignano⁵ and Francis Barbone¹, ¹GSK Consumer Healthcare, Warren, NJ, ²GSK Consumer Healthcare S.A., Nyon, Switzerland, ³PharmaLex US Corporation, Fairfax, VA, ⁴Walter Reed National Military Medical Center, Bethesda, ⁵Health ResearchTx LLC., Prevose, PA
Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
Abstract Number: 1636 • ACR Convergence 2020
8 Years Follow-Up of a Novel Autoinflammatory Disease: CD59 Malfunction Causes Hemolytic Anemia, Recurrent Guillain-Barre Syndrome, and Strokes in Pediatric Populations and Respond Well to Eculizumab and Pozelimab
Dror Mevorach¹ and Netanel Karbian¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: In 2013 we have described the first patients with a novel autoinflammatory disease manifested in 4 children with recurrent Guillain-Barre syndrome and hemolytic anemia…
Abstract Number: 1637 • ACR Convergence 2020
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Jun Shimizu¹, Yoshihisa Yamano¹, Kimito Kawahata² and Noboru Suzuki¹, ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…
Abstract Number: 1638 • ACR Convergence 2020
Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients
David Martinez-Lopez¹, Lara Sanchez-Bilbao², Carmen Alvarez-Reguera², Alba Herrero Morant², Inigo Gonzalez-Mazon³, José Luis Martín-Varillas⁴, Guillermo Suarez-Amorin², Patricia Setien-Preciados², Cristina Mata-Arnaiz⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Sierrallana, Torrelavega, Spain, ⁵Hospital de Laredo, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Behçet’s disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and…
Abstract Number: 1639 • ACR Convergence 2020
Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
Victoria Werth¹, Chester Oddis², David Fiorentino³, Nancy Dgetluck⁴, Quinn Dinh⁵, Michael Tillinger⁶, Barbara White⁵ and Ingrid Lundberg⁷, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Department of Dermatology, Stanford University, Redwood City, CA, ⁴Corbus Pharmaceuticals, Inc., Norwood, MA, ⁵Corbus Pharmaceuticals, Norwood, MA, ⁶Corbus Pharmaceuticals Inc., Norwood, MA, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden
Background/Purpose: There is significant unmet need for new treatments to achieve disease control in dermatomyositis (DM), because of limited efficacy or toxicity of immunosuppressive agents…
Abstract Number: 1640 • ACR Convergence 2020
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
Thomas Schnitzer¹, Francis Berenbaum², Philip G Conaghan³, Robert Dworkin⁴, Takaharu Yamabe⁵, Isabelle Davignon⁵, Stefan Wilhelm⁶, Erika Dragon⁷ and Lars Viktrup⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴University of Rochester School of Medicine and Dentistry, Rochester, NY, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Ltd, Budapest, Hungary
Background/Purpose: Tanezumab is under investigation for the treatment of moderate to severe OA pain. As part of the phase 3 OA program, two randomized, placebo-controlled…
Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter¹, Tuhina Neogi², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi², Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ²Boston University School of Medicine, Boston, MA, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1643 • ACR Convergence 2020
Evaluating Analgesic Response to Subcutaneous Tanezumab in Patients with Inadequate Treatment Response to Other Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo-controlled Studies
Thomas Schnitzer¹, Francis Berenbaum², Isabelle Davignon³, Ruoyong Yang⁴, Lars Viktrup⁵, Christine West³ and Kenneth Verburg⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc.,, New York, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Pfizer Inc, Groton
Background/Purpose: Tanezumab is a monoclonal antibody against nerve growth factor being investigated for treatment of the signs and symptoms of osteoarthritis (OA). Subcutaneous tanezumab was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].